CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-15). The draft was written by AI, the existence of all 1 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2614 · Search date 2026-08-15 · Methodology v0.7

Mobile stroke unit,
does it really help with Reduced disability and increased functional independence at 90 days?

30-Second Summary
C
Evidence Grade C · 54 · Safety caution
Functional outcomes improved, but this was not an individually randomized causal test of the mobile-unit system
Prehospital thrombolysis requires immediate specialist assessment of hemorrhage, time window, contraindications, and blood pressure. This is not an intervention for independent use by untrained individuals.
What the
research shows
The grade is C. In the 1,047 t-PA-eligible BEST-MSU analysis, mean 90-day utility-weighted mRS was 0.72 with mobile-unit care and 0.66 with conventional EMS, while favorable function corresponding to mRS 0 to 1 was 55.0% versus 44.4%. However, patients were assigned through prespecified alternating weeks rather than individual randomization, and enrollment was heavily concentrated in Houston, limiting causal certainty despite the large difference.
What the
ads claim
The result does not mean that purchasing a CT-equipped ambulance alone recreates the benefit. The intervention bundled specialist staffing, telemedicine or onboard neurology, point-of-care testing, t-PA protocols, and hospital integration.
*

Useful facts when choosing a product

  • The mobile unit bundled CT, point-of-care testing, paramedic and critical-care nursing staff, neurologic decision-making, and intravenous t-PA.
  • Assignment alternated designated mobile-unit and conventional-EMS weeks at each site rather than randomizing individual patients.
  • Genentech supplied t-PA at no cost but had no role in design, conduct, analysis, or reporting; primary study funding came from PCORI.
Gap Measurement · Verdict 2614 · C 54
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

BEST-MSU prospectively alternated designated mobile-unit and conventional-EMS weeks across seven cities. A total of 1,515 patients were enrolled; 617 versus 430 judged t-PA eligible by later blinded review entered the primary analysis. Median onset-to-t-PA time was 72 versus 108 minutes. The study used common clinical criteria plus blinded eligibility and 90-day assessment, but not patient-level randomization. The primary outcome in NCT02190500 matched the paper.

02

Why this is classified as C (54)

A publicly funded prospective study found better blinded 90-day function and a large absolute difference in independence, but nonrandom assignment and Houston-centered enrollment give C with 54 points.

Counterpoint. The effect belongs to a highly organized urban system. Effectiveness and cost-effectiveness need separate testing in rural areas and systems with different hours, staffing, and hospital networks.

Rejudgment record. Cross-check applied — A publicly funded prospective study found a large difference in blinded 90-day function, with patient-level nonrandom assignment and one-city enrollment concentration reflected

Scoring profile behind this grade
EndpointPPatient-reported treatment goal - the symptom is the goal
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (C).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Increased functional independence at 90 daysCmRS 0 to 1 was 55.0% versus 44.4%, but patients were not individually randomized.
Shorter onset-to-thrombolysis timeCMedian time was 72 versus 108 minutes.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Prospective seven-city alternating-week nonrandomized controlled trial430Public PCORI funding; t-PA and some study medication supplied at no costBlinded 90-day utility-weighted modified Rankin ScaleMean 0.72 versus 0.66; mRS 0 to 1 was 55.0% versus 44.4%, adjusted OR 2.43 (95% CI 1.75 to 3.36), P<0.001.Pivotal but nonrandomized prospective evidence
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-08-15).

Grotta JC, Yamal JM, Parker SA, et al. Prospective, multicenter, controlled trial of mobile stroke units. N Engl J Med. 2021;385(11):971-981. PMID: 34496173. DOI: 10.1056/NEJMoa2103879.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-15 · Corrections: none

Cite this verdict

Mobile stroke unit x 90-day disability Evidence Grade C card
[Chamgap] Mobile stroke unit x 90-day disability — Evidence Grade C·54. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/cognition/mobile-stroke-unit-90-day-disability/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.